Abstract Treatment‐resistant depression continues to pose a major medical challenge, as up
to one‐third of patients with major depressive disorder fail to have an adequate response to …

Abstract Treatment-resistant depression affects at least 1-3% of the US population. This
article reviews the current state of focal neuromodulation therapies for treatment-resistant …

Drugs and psychotherapy are inadequate for relieving depressive symptoms in a substantial
portion of severely depressed patients. In that patient group, neurostimulation techniques …

About 30% of patients suffering from a major depressive disorder do not respond sufficiently
to established pharmacological, psychotherapeutic, or somatic treatments. Advances in …

In the treatment of depression, when pharmacotherapy, psychotherapy and the oldest brain
stimulation techniques are deadlocked, the emergence of new therapies is a necessary …

Depression is the most prevalent debilitating mental illness; it is characterized as a disorder
of mood, cognitive function, and neurovegetative function. About one in ten individuals …

Electroconvulsive therapy (ECT) is the most effective acute treatment for a major depressive
episode. However, some patients do not achieve symptomatic remission with ECT, many …

Brain stimulation therapies have demonstrated efficacy in the treatment of depression and
treatment-resistant depression (TRD). Non-invasive brain stimulation in the treatment of …

Major depressive disorder (MDD) is a prevalent mental illness associated with significant
impairment in quality of life and treatment resistance in as many as 50% of patients. Few …

Background Deep brain stimulation (DBS) has been applied in treatment-resistant
depression (TRD) as a putative intervention targeting different brain regions. However, the …